1. Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype‐Derived Activity Scores
- Author
-
Zhichuan Li, Danxin Wang, Liang Zhao, Scott A. Mosley, Yan Gong, Rhonda M. Cooper-DeHoff, Minori Kinjo, Reginald F. Frye, Cameron D. Thomas, Taimour Y. Langaee, Arlene B. Chapman, Sarah Kim, Hyewon Kim, Larisa H. Cavallari, Issam Hamadeh, John G. Gums, David S. Estores, Siegfried Schmidt, Lanyan Fang, Julie A. Johnson, Stephan Schmidt, Nihal El Rouby, Karthik Lingineni, Kairui Feng, and Philip F. Binkley
- Subjects
Adult ,Male ,medicine.medical_specialty ,CYP2D6 ,Genotype ,Administration, Oral ,Blood Pressure ,Polymorphism, Single Nucleotide ,Gastroenterology ,Article ,Pharmacokinetics ,Heart Rate ,Internal medicine ,Heart rate ,medicine ,Humans ,Pharmacology (medical) ,Prospective Studies ,Aged ,Metoprolol ,business.industry ,Research ,Significant difference ,Articles ,Middle Aged ,Adrenergic beta-1 Receptor Antagonists ,Clinical Practice ,Phenotype ,Cytochrome P-450 CYP2D6 ,Pharmacogenetics ,Modeling and Simulation ,Pharmacodynamics ,Female ,business ,medicine.drug - Abstract
Recent CYP2D6 phenotype standardization efforts by CYP2D6 activity score (AS) are based on limited pharmacokinetic (PK) and pharmacodynamic (PD) data. Using data from two independent clinical trials of metoprolol, we compared metoprolol PK and PD across CYP2D6 AS with the goal of determining whether the PK and PD data support the new phenotype classification. S‐metoprolol apparent oral clearance (CLo), adjusted for clinical factors, was correlated with CYP2D6 AS (P
- Published
- 2020